Genomic and CTC Markers for Measuring Metastatic Risk in Breast Cancer Following Primary Treatment
The primary aim of the study is to identify genomic and circulating tumour cell (CTC) markers as biomarkers of response to chemotherapy among patients with invasive breast cancer. The secondary aim of this study is to use genomic and CTC markers to evaluate metastatic risk in breast cancer following primary treatments.
Primary Outcome:
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the Canadian Cancer Society